SAIK ANDREW (EVP & Chief Financial Officer) reported 1 transaction at INTERCEPT PHARMACEUTICALS, INC.
Review the transaction codes below to understand the nature of each event.
Filed: 1/3/2023ACC: 0001104659-23-000337
Officer· EVP & Chief Financial Officer
Since Jun 2021
-718.00
Net shares
Net seller
$8.9K
Total sold
0
Open market trades
0B · 0S
1
Total transactions
718.00 disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−718.00
Price / share
$12.37
Trade value
$8.88K
% of position
1.3%
12/31/2022
57.01K→56.29K
Total
Net shares
−718.00
Net value
-$8.88K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/31/2022 | F · Tax Withholding | −718.00 | $12.37 | $8.88K | 1.3% | 57.01K | 56.29K |
| Total | −718.00 | -$8.88K | ||||||
Derivative Transactions0
No derivative transactions reported